NCT02757586

Brief Summary

CLL is a disease of the elderly, identifying effective therapies with better toxicity profiles is thus a high priority, and targeted therapies may allow attainment of this goal.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2016

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 17, 2016

Completed
15 days until next milestone

First Posted

Study publicly available on registry

May 2, 2016

Completed
7 months until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

May 13, 2016

Status Verified

May 1, 2016

Enrollment Period

2 years

First QC Date

April 17, 2016

Last Update Submit

May 11, 2016

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Keywords

chronic lymphocytic leukemiaXPO1in vitroin vivo

Outcome Measures

Primary Outcomes (1)

  • overall response

    2 years

Interventions

shRNAGENETIC

Using shRNA interfered the expression of the gene of CLL

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

CLL patients

You may qualify if:

  • patients with CLL

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

PB

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

RNA, Small Interfering

Condition Hierarchy (Ancestors)

Leukemia, B-CellLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

RNA, AntisenseAntisense Elements (Genetics)Nucleic Acids, Nucleotides, and NucleosidesRNANucleic AcidsRNA, Small UntranslatedRNA, Untranslated

Study Officials

  • Xiao-Jun Huang

    professor

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiao-Hui Zhang, Doctor

CONTACT

861088324577zhangxh100@sina.com

Ru Feng, Doctor

CONTACT

861085136381frbld@sina.com

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2016

First Posted

May 2, 2016

Study Start

December 1, 2016

Primary Completion

December 1, 2018

Study Completion

December 1, 2019

Last Updated

May 13, 2016

Record last verified: 2016-05